New drug shows promise against multiple Hard-to-Treat cancers

NCT ID NCT04482309

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 19 times

Summary

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with several types of advanced cancers that have a specific protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, and rare tumors will receive the drug and be monitored for response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PART 1: BLADDER, BILIARY TRACT, CERVICAL, ENDOMETRIAL, OVARIAN, PANCREATIC CANCER, RARE TUMORS, ANY TUMOR TYPE EXCLUDING BREAST, GASTRIC, COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    Santa Rosa, California, 95403, United States

  • Research Site

    Chicago, Illinois, 60637, United States

  • Research Site

    Muncie, Indiana, 47303, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    Middletown, New Jersey, 07748, United States

  • Research Site

    Harrison, New York, 10604, United States

  • Research Site

    New York, New York, 10029, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Durham, North Carolina, 27710, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Seattle, Washington, 98195, United States

  • Research Site

    Auchenflower, 4066, Australia

  • Research Site

    Blacktown, 2148, Australia

  • Research Site

    Camperdown, 2050, Australia

  • Research Site

    Heidelberg, 3084, Australia

  • Research Site

    Melbourne, 3000, Australia

  • Research Site

    Nedlands, 6009, Australia

  • Research Site

    Brussels, 1090, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Liège, 4000, Belgium

  • Research Site

    Porto Alegre, 90035-000, Brazil

  • Research Site

    São Paulo, 01246-000, Brazil

  • Research Site

    Vitória, 29043-272, Brazil

  • Research Site

    Kelowna, British Columbia, V1Y 5L3, Canada

  • Research Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    Québec, Quebec, G1J 1Z4, Canada

  • Research Site

    Montreal, H3T 1E2, Canada

  • Research Site

    Brno, 656 53, Czechia

  • Research Site

    Hradec Králové, 500 05, Czechia

  • Research Site

    Olomouc, 77900, Czechia

  • Research Site

    Prague, 150 06, Czechia

  • Research Site

    Prague, 180 81, Czechia

  • Research Site

    Delhi, 110085, India

  • Research Site

    Gurgaon, 122001, India

  • Research Site

    Kolkata, 700160, India

  • Research Site

    Mumbai, 400012, India

  • Research Site

    Milan, 20162, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Rome, 168, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Kashiwa, 277-8577, Japan

  • Research Site

    Suita-shi, 565-0871, Japan

  • Research Site

    Amsterdam, 1066CX, Netherlands

  • Research Site

    Delft, 2625 AD, Netherlands

  • Research Site

    Groningen, 9700, Netherlands

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Krakow, 31-501, Poland

  • Research Site

    Poznan, 60-355, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Kaluga, 248007, Russia

  • Research Site

    Moscow, 115419, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 117997, Russia

  • Research Site

    Moscow, 121205, Russia

  • Research Site

    Moscow, 143423, Russia

  • Research Site

    Moscow, 143442, Russia

  • Research Site

    Saint Petersburg, 195271, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 5505, South Korea

  • Research Site

    Barcelona, 8035, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    Madrid, 28027, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Madrid, 28046, Spain

  • Research Site

    Valencia, 46014, Spain

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 736, Taiwan

  • Research Site

    Taipei, 100, Taiwan

  • Research Site

    Taipei, 10449, Taiwan

  • Research Site

    Taipei, 11217, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Bangkok, 10210, Thailand

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10400, Thailand

  • Research Site

    Chiang Mai, 50200, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

  • Research Site

    Khon Kaen, 40002, Thailand

  • Research Site

    Muang, 50200, Thailand

  • Research Site

    Ongkharak, 26120, Thailand

  • Research Site

    London, SW2 6JJ, United Kingdom

  • Research Site

    Manchester, M20 4BX, United Kingdom

  • Research Site

    Sutton, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.